Ann Diagn Pathol 2017 Jun 10;28:54-59. Epub 2017 Feb 10.

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address:

Background: Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Read More

J Cutan Pathol 2017 Jun 19. Epub 2017 Jun 19.

Los Angeles Medical Center (LAMC), Southern California Kaiser Permanente, Department of Dermatology, Los Angeles, California, USA.

Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell non-Hodgkin lymphoma with two main clinical presentations: primary cutaneous (pcALCL) and systemic (sALCL). While rare cases of myxoid sALCL have been reported, there are no previous cases of myxoid pcALCL reported. We present two unusual cases of pcALCL showing prominent collections of dermal mucin closely intermingling with the anaplastic lymphocytes. Read More

J Cutan Med Surg 2017 Jun 1:1203475417716366. Epub 2017 Jun 1.

1 Division of Dermatology, University of Toronto, Toronto, ON, Canada.

Background: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies.

Objective: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies. Read More

Lancet 2017 06 6. Epub 2017 Jun 6.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. Read More

Am J Dermatopathol 2017 May 22. Epub 2017 May 22.

*Professor of Pathology, Pathologist and Dermatopathologist, Director of Dermatopathology Division, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY; †Dermatopathology Fellow, Memorial Sloan Kettering Cancer Center/Weill Cornell Medicine, New York, NY; and ‡Assistant Professor of Clinical Dermatology, Department of Dermatology, UCDAVIS Health Center, Sacramento, CA.

Primary cutaneous anaplastic large cell lymphoma (ALCL), similar to systemic ALCL, has as its histomorphologic hallmarks cohesive sheets of large lymphoid cells expressing CD30. Several morphologic variants of systemic ALCL have been reported, including the common (classic) type, lymphohistiocytic, and small cell variants. The small cell variant of ALCL is characterized by a predominant cytomorphology which is unexpected for ALCL, being in the context of a small- to medium-sized hyperchromatic atypical lymphocyte. Read More

Br J Dermatol 2017 Jun 1. Epub 2017 Jun 1.

Department of Dermatology, AP-HP, St Louis Hospital, Paris 7 University, Paris, France.

Lymphomatoid papulosis (LyP) is considered as an indolent CD30+ lymphoproliferative cutaneous disorder. (1,2) Nevertheless, 10%-20% up to 50% of patients with LyP have coexistent lymphoma. (1, 3-7) The most frequently associated malignancies are mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or Hodgkin's disease. Read More

J Cutan Pathol 2017 May 12. Epub 2017 May 12.

Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

CD8-positive, CD30-positive cutaneous lymphoproliferative disorders comprise a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma. These entities share overlapping clinical, histopathologic and immunophenotypic features, presenting both a clinical and pathological diagnostic challenge. Presented here is a 73-year-old man with a disseminated, indolent CD30+, CD8+ cutaneous lymphoproliferative disorder with overlapping clinical and histopathological features of both mycosis fungoides and primary cutaneous ALCL, as well as features of lymphomatoid papulosis. Read More

Crit Rev Oncol Hematol 2017 May 27;113:8-17. Epub 2017 Feb 27.

Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.

Background: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. Read More

J Cutan Pathol 2017 Jun 25;44(6):570-577. Epub 2017 Apr 25.

Department of Pathology, Stanford University School of Medicine, Stanford, California.

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms. Read More

Hematol Oncol Clin North Am 2017 Apr;31(2):317-334

Department of Dermatology, The Center for Cutaneous Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address:

Primary cutaneous CD30(+) lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. Read More

J Cutan Pathol 2017 Mar 23. Epub 2017 Mar 23.

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.

Chronic lymphedema predisposes to develop malignant cutaneous tumors, including angiosarcoma, Kaposi's sarcoma and B-cell lymphoma. T-cell malignancy has rarely been associated with chronic lymph stasis. Here, we report a case of primary cutaneous anaplastic large cell lymphoma (pcALCL) with lymphatic spread associated with chronic lymphedema. Read More

Dermatol Pract Concept 2017 Jan 31;7(1):59-61. Epub 2017 Jan 31.

Second University of Naples, Department of Dermatology, Naples, Italy.

Primary cutaneous CD 30 (+) anaplastic large cell lymphoma (PCALCL) is a rare and indolent type of cutaneous T cell lymphoma, which usually presents as an asymptomatic solitary firm nodule that rapidly grows and often ulcerates without any systemic involvement. A 64-year-old female presented to our outpatient clinic with a one-year history of multiple pink nodular lesions on the chest, back and gluteal regions. Dermoscopic examination of the nodular lesions revealed pink-to-yellow structureless areas and arborizing-to-polymorphous vessels. Read More

An Bras Dermatol 2017 Jan-Feb;92(1):86-91

Hospital Federal de Bonsucesso - Bonsucesso (RJ), Brazil.

The classification of cutaneous lymphomas is multidisciplinary and requires the correlation between clinical, histopathological, immunohistochemical, and molecular diagnostic elements. In this article, we present four different cases of CD30-positive T-cell lymphoma with cutaneous manifestations. We compare cases with definitive diagnosis of papulosis lymphomatoid type C, primary cutaneous anaplastic large T-cell lymphoma, systemic anaplastic large T-cell lymphoma with secondary skin involvement, and mycosis fungoides with large cell transformation, highlighting the importance of clinicopathological correlation to classify these cases. Read More

Hum Pathol 2017 Jun 30;64:19-27. Epub 2017 Jan 30.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address:

Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue TP63 in a subset of cases that demonstrate aggressive clinical behavior. In the present study, we examined the relationship between p63 protein expression by immunohistochemistry and the results of fluorescence in situ hybridization using TP63 probes in 116 ALCLs. We also determined the relative expression of full-length TAp63 and truncated ΔNp63 isoforms (eg, p40) in ALCL cell lines and a subset of clinical cases. Read More

Semin Diagn Pathol 2017 Jan 29;34(1):22-35. Epub 2016 Nov 29.

Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:

Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

Clin Dermatol 2016 Nov - Dec;34(6):749-759. Epub 2016 Jul 10.

Department of Dermatology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030.

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. Read More

Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.

a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.

Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

Cutis 2016 Oct;98(4):253-256

Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.

Primary cutaneous anaplastic large-cell lymphoma (pcALCL) is part of a spectrum of CD30+ primary cutaneous lymphoproliferative disorders (pcLPDs) that also includes lymphomatoid papulosis (LyP). Localized radiotherapy at doses of 34 to 44 Gy is first-line treatment of pcALCL, but the use of low-dose radiotherapy for pcALCL has not been reported. We present the case of a patient with a history of pcALCL/LyP who was treated with low-dose radiotherapy while on oral low-dose methotrexate (MTX) once weekly. Read More

Br J Haematol 2017 Jan 21;176(2):234-240. Epub 2016 Oct 21.

Department of Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.

Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare CD30(+) lymphoproliferative disorder with excellent outcomes reported despite frequent cutaneous relapses. Limited information exists on the development of systemic lymphoma. The British Columbia Cancer Agency (BCCA) Lymphoid Cancer Database was searched to identify all adults diagnosed with PCALCL from 1993 to 2013. Read More

J Cutan Pathol 2016 Nov 30;43(11):963-973. Epub 2016 Aug 30.

1st Department of Pathology and Experimental Cancer Research Institute, Semmelweis University, Budapest, Hungary.

Lymphomatoid papulosis (LyP) belongs to CD30+ lymphoproliferative disorders with indolent clinical course. Classic histological subtypes, A, B and C are characterized by the CD4+ phenotype, while CD8+ variants, most commonly classified as type D, were reported in recent years. We present 14 cases of CD8+ LyP. Read More

J Cutan Pathol 2016 Nov 26;43(11):1041-1044. Epub 2016 Aug 26.

Department of Pathology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.

Lymphomatoid papulosis (LyP) is classified as a CD30+ primary cutaneous lymphoproliferative disease. The phenotypic variability along the spectrum of CD30+ lymphoproliferative diseases is highlighted by the distinct histologic subtypes of LyP types A, B, C, and the more recently described types D, E, and F. We report the case of an elderly woman with a clinical presentation and histopathologic findings consistent with LyP, whose atypical CD30+ infiltrate uniquely demonstrated a spindle-cell morphology. Read More

Anticancer Agents Med Chem 2016 Sep 2. Epub 2016 Sep 2.

Division of Hematology, University Hospital Viale Bracci - 53100 Siena, Italy.

The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers' effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL) the maximum tolerated dose was fixed at 1. Read More

Ann Dermatol 2016 Aug 26;28(4):491-4. Epub 2016 Jul 26.

Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

CD30+ lymphoproliferative disorders (LPD) represent a spectrum of T-cell lymphoma including lymphomatoid papulosis and anaplastic large cell lymphoma (ALCL). Epidermis overlying cutaneous CD30+ LPD often shows epidermal hyperplasia, hyperkeratosis, crusting, and ulceration and it is difficult to distinguish from carcinoma such as keratoacanthoma (KA) or squamous cell carcinoma (SCC). Several cases of pseudocarcinomatous hyperplasia mimicking KA or SCC in CD30+ LPD have been reported. Read More

Diagn Cytopathol 2017 Jan 29;45(1):51-54. Epub 2016 Jul 29.

Department of Cytology and Cytogenetic, University Hospital Merkur, Zagreb, Croatia.

ALK positive anaplastic large cell lymphoma is a T-cell lymphoma usually occurring in children and young adults. It frequently involves lymph nodes and extranodal sites and is associated with favorable prognosis. A 20-year old man was admitted for painful mass in the left axilla with overlying skin redness. Read More

Expert Rev Hematol 2016 Aug 14;9(8):767-80. Epub 2016 Jul 14.

a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.

Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.

Areas Covered: Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Read More

J Drugs Dermatol 2016 Jul;15(7):894-5

Monoclonal antibody therapy is a new innovation in cancer therapy. Binding of monoclonal antibodies to tumor cells facilitates their destruction by the immune system. Tumor cells with mutated target antigens may escape detection by monoclonal antibodies and exhibit a selective growth advantage. Read More

Infect Agent Cancer 2016 5;11:31. Epub 2016 Jul 5.

Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy.

Background: We have previously reported the case of an immunocompetent female patient with a primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) located on her upper right eyelid characterized by the presence of a concurrent active infection by C. pneumoniae and Human herpesvirus 8 (HHV8). This finding suggested for the first time a possible association of C. Read More

Am J Blood Res 2016 18;6(1):1-5. Epub 2016 May 18.

Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center Louisville, Kentucky, USA.

Methotrexate (MTX) is a commonly used anti-metabolite agent. Increased risk of lymphoproliferative disorders (LPD) in patients with rheumatoid arthritis (RA) has been documented with the prolonged use of immunosuppressive medications such as MTX. This is thought to be the result of immune dysregulation and/or chronic immune stimulation. Read More

Ann Dermatol 2016 Jun 25;28(3):371-4. Epub 2016 May 25.

Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.

Anaplastic large-cell lymphoma (ALCL) is a CD30-positive T-cell/null-cell lymphoma that is clinically classified into either primary cutaneous ALCL or systemic ALCL (S-ALCL) sub-types. Because 90% of childhood S-ALCL cases are anaplastic lymphoma kinase (ALK)-positive, there is a lack of data on ALK-negative S-ALCL cases among pediatric patients. Herein, we report a rare case of ALK-negative S-ALCL in a 9-year-old Korean boy who initially presented with itchy erythematous maculopapules and an erosive nodule on the trunk area. Read More

Mult Scler 2016 Dec 26;22(14):1888-1890. Epub 2016 Apr 26.

Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.

Background: The appearance of solid tumors und lymphomas during treatment with fingolimod was observed in studies and has been described in case reports.

Objective: To report a case of primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis (MS) with fingolimod.

Methods: Case study. Read More

J Cutan Pathol 2016 Jul 8;43(7):579-88. Epub 2016 May 8.

Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.

Background: The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30-positive lymphoproliferative disorders.

Methods: We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large-cell lymphoma (PC-ALCL: 8 specimens), and reactive diseases harboring CD30-positive cells (18 specimens). Read More

Br J Dermatol 2016 Aug 13;175(2):325-33. Epub 2016 Jul 13.

Université Paris-Diderot, Sorbonne Paris Cité, Paris, 75010, France.

Background: KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.

Objectives: To examine the expression of KIR3DL2 and its potential use as a therapeutic target in patients with primary cutaneous anaplastic large-cell lymphoma (pcALCL), the most aggressive cutaneous CD30(+) lymphoproliferative disease. Read More

Am J Dermatopathol 2016 May;38(5):388-92

*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; †Department of Dermatology, Mayo Clinic, Rochester, MN, Dr. Cohen is now affiliated with the Department of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (As of/After July 1, 2015); ‡Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN; and §Departments of Laboratory Medicine and Pathology, and Dermatology, Mayo Clinic, Rochester, MN.

CD30-positive cutaneous lymphoproliferative disorders, a group of T-cell neoplasms, including lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma, require careful clinicopathologic correlation for diagnosis. An association between LyP and the development of a second hematolymphoid malignancy has been established in the literature. LyP has also been reported with systemic amyloidosis, but no such reports have documented coexisting cutaneous amyloid deposition with LyP to our knowledge. Read More

Aesthet Surg J 2016 Jul 15;36(7):773-81. Epub 2016 Mar 15.

Dr Kadin is a Professor of Dermatology, Boston University School of Medicine, Boston, MA; and a Staff Physician, Roger Williams Medical Center, Providence, RI. Dr Deva is an Associate Professor of Cosmetic, Plastic, and Reconstructive Surgery, Macquarie University, NSW, Australia. Ms Xu is a Research Assistant, Dr Morgan is Director of the Research Core Facility, and Dr Khare is Director of the Cancer Immunotherapy and Gene Therapy Facility, Roger Williams Medical Center, Providence, RI. Dr MacLeod is Director of Cytogenetics at the Leibniz Institute, DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. Dr Van Natta is an Associate Clinical Professor, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN. Dr Adams is an Associate Clinical Professor, Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX. Dr Brody is Professor Emeritus in the Division of Plastic Surgery, and Dr Epstein is a Professor of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA.

Almost 200 women worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The unique location and specific lymphoma type strongly suggest an etio-pathologic link between breast implants and BIA-ALCL. It is postulated that chronic inflammation via bacterial infection may be an etiological factor. Read More

Dermatol Ther 2016 Jul 11;29(4):224-7. Epub 2016 Mar 11.

Department of dermatology, Nan Fang Hospital, Guangzhou, China.

Primary cutaneous anaplastic large-cell lymphoma (PCALCL) is a part of the spectrum of CD30+ lymphoproliferative cutaneous processes. The characteristics include single or multifocal nodules that ulcerate as skin lesion, slow disease progression, autoregressive, and recurrent in few years. The present study report the case of a 16-year-old boy presenting PCALCL with single nodules, ulcer, keloid, and scab in his right-side face. Read More

J Cutan Pathol 2016 Jul 5;43(7):602-608. Epub 2016 Apr 5.

Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.

Breast implant-associated anaplastic large cell lymphoma (ALCL) is a newly described clinical and pathologic entity that typically presents as seroma in the fibrous scar around the implant. Less frequently, it presents as a solid peri-implant mass, and there have been no reports to date of cutaneous lesions as the presenting manifestation. We report the case of a 56-year-old woman with a history of bilateral breast reconstruction following breast cancer of the right breast who consulted with several papules on the right breast suggestive of metastasis. Read More

Ann Hematol 2016 Apr 2;95(5):847-9. Epub 2016 Mar 2.

Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.

Expert Rev Anticancer Ther 2016 18;16(3):279-83. Epub 2016 Feb 18.

a Hematology and Medical Oncology , Loma Linda University , Loma Linda , CA , United States.

Unlabelled: Anaplastic large cell lymphoma (ALCL) is a rare hematological malignancy and a distinct subtype of mature T-cell lymphomas. ALCL is comprised of two clinically distinct but morphologically similar sub-class under 2008 WHO classification: cutaneous and systemic. Primary systemic ALCL is further sub-categorized into tumors that carry the anaplastic lymphoma kinase (ALK) gene rearrangement or not; ALK-positive versus ALK-negative disease respectively. Read More

Acta Med Iran 2015 Dec;53(12):785-8

Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Primary cutaneous anaplastic large cell lymphoma is a T-cell malignancy with atypical CD30 positive lymphocytes. Pseudoepitheliomatous hyperplasia is an uncommon finding in primary cutaneous anaplastic large cell lymphoma, and may mimic squamous cell carcinoma as pseudomalignancy. Careful attention of a pathologist to correct diagnosis of pseudoepitheliomatous hyperplasia and its underlying causes will help physicians to avoid inappropriate management. Read More

Am J Dermatopathol 2016 Jan;38(1):e1-10

Departments of *Dermatology and Cutaneous Biology; †Surgery, Thomas Jefferson University, Philadelphia, PA; and ‡Dermatologist and Dermatopathologist, Bryn Mawr Skin and Cancer Institute, Main Line Health, Bryn Mawr, PA.

Lymphomatoid papulosis (LyP) is an uncommon CD30 lymphoproliferative disorder with a relatively excellent prognosis. Ten to twenty percent of cases, however, are associated with a lymphoma, typically systemic or cutaneous anaplastic large cell lymphoma, mycosis fungoides, or Hodgkin lymphoma. Subtypes divide LyP into infiltrate-descriptive categories along a spectrum of histological manifestation. Read More

Indian J Dermatol Venereol Leprol 2016 Jan-Feb;82(1):53-6

Department of Dermatology, Lady Hardinge Medical College, New Delhi, India.

Non-Hodgkin lymphoma is a common childhood T-cell and B-cell neoplasm that originates primarily from lymphoid tissue. Cutaneous involvement can be in the form of a primary extranodal lymphoma, or secondary to metastasis from a non-cutaneous location. The latter is uncommon, and isolated cutaneous involvement is rarely reported. Read More

Dermatol Online J 2016 Oct 15;22(10). Epub 2016 Oct 15.

Medical School, University of California, San Diego, CA, USA.

Background CD30+ lymphoproliferative disorders are rare and may feature a wide variety of presentations that mimic other conditions. Purpose A man with metastatic papillary thyroid carcinoma to skin who subsequently developed cutaneous anaplastic large cell lymphoma is described. Methods The PubMed medical database was used to search the following terms separately and in combination: ALCL, anaplastic large cell lymphoma ALCL, cutaneous anaplastic large cell lymphoma CALCL, cutaneous t-cell lymphoma CTCL, large t-cell lymphoma LTCL, lymphoproliferative, lymphomatoid papulosis LyP, mimic, papillary, thyroid cancer. Read More

Clin Lymphoma Myeloma Leuk 2016 Feb 1;16(2):e15-9. Epub 2015 Dec 1.

Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX.

Haematologica 2016 Mar 24;101(3):e103-6. Epub 2015 Dec 24.

Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Unité INSERM U955, Créteil, France Université Paris Est, Créteil, France

Clin Lymphoma Myeloma Leuk 2016 Jan 1;16(1):49-56. Epub 2015 Dec 1.

Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Introduction: Large cell transformation (LCT) of mycosis fungoides (MF) is associated with an aggressive clinical course, poor overall survival (OS), and variable CD30 expression.

Patients And Methods: We retrospectively analyzed 1900 MF/Sézary syndrome patients' clinical, histologic and immunophenotype and identified 187 patients seen between 1982 and 2012.

Results: Most advanced stage patients with LCT were male 86 of 155 (55. Read More

J Cutan Pathol 2016 Apr 11;43(4):400-5. Epub 2016 Feb 11.

Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain.

Primary cutaneous anaplastic large cell lymphoma is a rare type of cutaneous T-cell lymphoma, and the involvement of the ocular adnexa is extremely rare. Secondary xanthoma-like changes after radiation therapy or chemotherapy have been rarely reported in association with large-cell T-cell anaplastic lymphoma. We report one case of a primary C-anaplastic large cell lymphoma affecting the eyelid with fast progression with multiple nodules in various anatomic sites and development of xanthoma-like lesions after treatment. Read More

Rev Med Chil 2015 Oct;143(10):1351-5

Primary cutaneous anaplastic large cell lymphoma (PCALCL) is within the spectrum of cutaneous CD30-positive lymphoproliferative disorders. It presents as localized or multifocal tumors or plaques and carries an excellent long-term prognosis even in cases with regional and/or ipsilateral lymph node involvement or in cases of recurrent disease. We report a 34 year-old female with a thigh lesion. Read More

J Am Acad Dermatol 2016 Jan 28;74(1):59-67. Epub 2015 Oct 28.

Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.

Background: Lymphomatoid papulosis (LyP) is a CD30(+) lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology.

Objective: The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center.

Methods: Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. Read More

Am J Dermatopathol 2015 Nov;37(11):822-33

*Department of Dermatology, New York University School of Medicine, New York, NY; †Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; ‡San Diego Pathologists Medical Group, Los Angeles, CA; §Department of Dermatology, University of Chicago Pritzker School of Medicine; and ¶Department of Pathology, Southern California Permanente Medical Group, Sunset Medical Center, Los Angeles, CA.

CD30 primary cutaneous lymphoproliferative diseases include both lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (PCALCL). The neoplastic cell of most primary CD30 lymphoproliferative disorders is CD4 positive. The terminology LyP "type D" has been used to describe a growing number of cases of LyP with a predominantly CD8 infiltrate. Read More

Acta Derm Venereol 2016 Mar;96(3):394-5

Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.